{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:09:10Z","timestamp":1789081750941,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82474260"],"award-info":[{"award-number":["82474260"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Oriental Scholar Leading Talent Project of Shanghai","award":["2022079"],"award-info":[{"award-number":["2022079"]}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"crossref","award":["2025BZ011"],"award-info":[{"award-number":["2025BZ011"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This scientometric study critically evaluates the global evolution of myelodysplastic syndromes (MDS) research from 2014 to 2025, aiming to integrate fragmented knowledge and identify emerging trends. A scientometric analysis was conducted using data retrieved from the Web of Science Core Collection on August 2, 2025. The search was restricted to \u201carticle\u201d and \u201creview\u201d in English containing \u201cMyelodysplastic syndrome\u201d or \u201cMyelodysplastic syndromes\u201d in the abstract, covering the period from January 1, 2014 onward. Scientometric tools (VOSviewer, CiteSpace, R-bibliometrix) were employed to analyze annual publication trends, country\/institution\/author contributions, collaboration networks, journal distribution, reference co-citation clusters, emerging research topics. Analysis of 6,822 publications revealed that global MDS research output peaked in 2021. The USA dominated with 2,838 publications, followed by China (1,169) and Germany (717), while top institutions (e.g., University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center) and prolific authors (e.g., Garcia-Manero G, Kantarjian HM) were predominantly USA-based. Collaboration networks revealed a core-periphery structure with strong transatlantic ties and emerging Asian contributions. Thematic analysis identified research hotspots across multiple dimensions, including\n                    <jats:italic>5q deletion<\/jats:italic>\n                    ,\n                    <jats:italic>trisomy 8<\/jats:italic>\n                    ,\n                    <jats:italic>germline predisposition<\/jats:italic>\n                    ,\n                    <jats:italic>TP53 mutation<\/jats:italic>\n                    ,\n                    <jats:italic>clonal hematopoiesis<\/jats:italic>\n                    ,\n                    <jats:italic>inflammation<\/jats:italic>\n                    ,\n                    <jats:italic>venetoclax<\/jats:italic>\n                    ,\n                    <jats:italic>luspatercept<\/jats:italic>\n                    ,\n                    <jats:italic>targeted therapy<\/jats:italic>\n                    ,\n                    <jats:italic>immunotherapy<\/jats:italic>\n                    ,\n                    <jats:italic>pediatric population<\/jats:italic>\n                    ,\n                    <jats:italic>VEXAS syndrome<\/jats:italic>\n                    ,\n                    <jats:italic>IPSS-R<\/jats:italic>\n                    ,\n                    <jats:italic>relapse<\/jats:italic>\n                    ,\n                    <jats:italic>prognosis<\/jats:italic>\n                    ,\n                    <jats:italic>overall survival<\/jats:italic>\n                    , and\n                    <jats:italic>artificial intelligence<\/jats:italic>\n                    . MDS research is shifting toward precision medicine. Future advances are expected to rely on multi-ethnic cohort building, mechanism exploration, combined treatment regimen optimization and novel drug development. Strengthening multidisciplinary collaboration is anticipated to facilitate clinical translation and foster more precise, equitable and clinically practical management of MDS globally.\n                  <\/jats:p>","DOI":"10.1007\/s10238-026-02226-z","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:04:07Z","timestamp":1782399847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the research landscape of myelodysplastic syndromes: a scientometric analysis (2014\u20132025)"],"prefix":"10.1007","volume":"26","author":[{"given":"Jieyun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Song","family":"Seetoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuncun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"14","key":"2226_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic Syndromes. N Engl J Med. 2020;383(14):1358\u201374.","journal-title":"N Engl J Med"},{"issue":"3","key":"2226_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.6004\/jnccn.2025.0013","volume":"23","author":"PL Greenberg","year":"2025","unstructured":"Greenberg PL, Stone RM, Abaza Y, et al. NCCN Guidelines\u00ae Insights: Myelodysplastic Syndromes, Version 2.2025. J Natl Compr Cancer Network: JNCCN. 2025;23(3):66\u201375.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"7","key":"2226_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"11","key":"2226_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"12","key":"2226_CR5","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365.","journal-title":"Blood"},{"issue":"7","key":"2226_CR6","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008.","journal-title":"NEJM Evid"},{"issue":"7","key":"2226_CR7","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873\u201389.","journal-title":"Leukemia"},{"issue":"14","key":"2226_CR8","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456\u201365.","journal-title":"N Engl J Med"},{"issue":"10","key":"2226_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","volume":"133","author":"U Platzbecker","year":"2019","unstructured":"Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096\u2013107.","journal-title":"Blood"},{"key":"2226_CR10","doi-asserted-by":"publisher","first-page":"101033","DOI":"10.1016\/j.blre.2022.101033","volume":"59","author":"Z Xie","year":"2023","unstructured":"Xie Z, Chen EC, Stahl M, Zeidan AM. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. Blood Rev. 2023;59:101033.","journal-title":"Blood Rev"},{"issue":"2","key":"2226_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.clml.2022.11.002","volume":"23","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Wei AH, Garcia-Manero G, et al. Azacitidine Monotherapy in Patients With Treatment-Na\u00efve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clin lymphoma myeloma Leuk. 2023;23(2):127\u201337.","journal-title":"Clin lymphoma myeloma Leuk"},{"issue":"26","key":"2226_CR12","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1182\/blood.2023020079","volume":"142","author":"ES Hellstr\u00f6m-Lindberg","year":"2023","unstructured":"Hellstr\u00f6m-Lindberg ES, Kr\u00f6ger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023;142(26):2268\u201381.","journal-title":"Blood"},{"key":"2226_CR13","doi-asserted-by":"crossref","unstructured":"Stagno F, Mirabile G, Rizzotti P et al. Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment. Biomedicines 2025;13(4).","DOI":"10.3390\/biomedicines13040835"},{"key":"2226_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152469","author":"JM Stempel","year":"2025","unstructured":"Stempel JM, Kewan T, Zeidan AM. Advances and challenges in the management of myelodysplastic syndromes. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17152469.","journal-title":"Cancers."},{"issue":"11","key":"2226_CR15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/ajh.25950","volume":"95","author":"G Garcia-Manero","year":"2021","unstructured":"Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. American journal of hematology. 2021;95(11):1399\u2013420.","journal-title":"American journal of hematology"},{"issue":"4","key":"2226_CR16","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3390\/curroncol31040148","volume":"31","author":"D Karel","year":"2024","unstructured":"Karel D, Valburg C, Woddor N, Nava VE, Aggarwal A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr Oncol (Toronto Ont). 2024;31(4):1971\u201393.","journal-title":"Curr Oncol (Toronto Ont)"},{"issue":"13","key":"2226_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood.2023023717","volume":"145","author":"U Borate","year":"2025","unstructured":"Borate U, Pugh K, Waller A, et al. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025;145(13):1369\u201381.","journal-title":"Blood"},{"key":"2226_CR18","doi-asserted-by":"crossref","unstructured":"Bewersdorf JP, Xie Z, Bejar R, et al. Current landscape of translational and clinical research in myelodysplastic syndromes\/neoplasms (MDS): proceedings from the 1(st) International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS). Blood reviews. 2023;60:101072, 101072.","DOI":"10.1016\/j.blre.2023.101072"},{"issue":"10","key":"2226_CR19","doi-asserted-by":"publisher","first-page":"e0223994","DOI":"10.1371\/journal.pone.0223994","volume":"14","author":"C Chen","year":"2019","unstructured":"Chen C, Song M. Visualizing a field of research: A methodology of systematic scientometric reviews. PLoS ONE. 2019;14(10):e0223994.","journal-title":"PLoS ONE"},{"issue":"6","key":"2226_CR20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/0193841X251336839","volume":"49","author":"AD Hoang","year":"2025","unstructured":"Hoang AD. Evaluating Bibliometrics Reviews: A Practical Guide for Peer Review and Critical Reading. Eval Rev. 2025;49(6):1074\u2013102.","journal-title":"Eval Rev"},{"key":"2226_CR21","doi-asserted-by":"crossref","unstructured":"Ma JZW, Li J, Zhai Y, Shen L. Bibliometric analysis of the Global Myelodysplastic Syndrome Study 1998\u20132022. Preprint Res Square 2023.","DOI":"10.21203\/rs.3.rs-2789742\/v1"},{"issue":"16","key":"2226_CR22","first-page":"88","volume":"19","author":"XY Hao","year":"2022","unstructured":"Hao XY, Kexin H, Tingting X, Yanlu W, Xiaojie D, Jiehui L. Bibliometric and visualization analysis of research on pathogenesis of myelodysplastic syndromes. China Med Herald. 2022;19(16):88\u201392.","journal-title":"China Med Herald"},{"key":"2226_CR23","doi-asserted-by":"crossref","unstructured":"Gill H, Yim R, Lee P, Lee CYY, et al. A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia. Blood Cancer J. 2025;15(1):128.","DOI":"10.1038\/s41408-025-01339-0"},{"issue":"12","key":"2226_CR24","doi-asserted-by":"publisher","first-page":"7687","DOI":"10.1097\/JS9.0000000000001876","volume":"110","author":"X Zeng","year":"2024","unstructured":"Zeng X, Shu B, Zeng Q, et al. A bibliometric and visualization analysis of global research status and frontiers on autophagy in cardiomyopathies from 2004 to 2023. Int J Surg (London England). 2024;110(12):7687\u2013700.","journal-title":"Int J Surg (London England)"},{"issue":"15","key":"2226_CR25","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00266-024-03983-6","volume":"48","author":"X Zhang","year":"2024","unstructured":"Zhang X, Li B, Mao J, et al. A Bibliometric and Visualisation Analysis on the Research of Female Genital Plastic Surgery Based on the Web of Science Core Collection Database. Aesthetic Plast Surg. 2024;48(15):2975\u201393.","journal-title":"Aesthetic Plast Surg"},{"issue":"2","key":"2226_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523\u201338.","journal-title":"Scientometrics"},{"issue":"1Suppl 1","key":"2226_CR27","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1073\/pnas.0307513100","volume":"101","author":"C Chen","year":"2004","unstructured":"Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA. 2004;101(1Suppl 1):5303\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2226_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"MCC Aria","year":"2017","unstructured":"Aria MCC. bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959\u201375.","journal-title":"J Informetr"},{"issue":"2","key":"2226_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"issue":"22","key":"2226_CR30","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327. quiz 3699.","journal-title":"Blood"},{"key":"2226_CR31","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1182\/blood-2022-159335","volume":"140","author":"MG Jean","year":"2022","unstructured":"Jean MG, Sabile AK, Tomic K, Manu G, Ronan T, Swords. Yazan Migdady. A Retrospective Validation Study Comparing the IPSS-M and IPSS-R Risk Stratification Scores in Primary and Secondary Myelodysplastic Syndrome (MDS). Blood. 2022;140:4088\u20139.","journal-title":"Blood"},{"issue":"10","key":"2226_CR32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","volume":"133","author":"S Ogawa","year":"2019","unstructured":"Ogawa S. Genetics of MDS. Blood. 2019;133(10):1049\u201359.","journal-title":"Blood"},{"issue":"1","key":"2226_CR33","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.joi.2020.101102","volume":"15","author":"B \u00c1lvarez-Bornstein","year":"2021","unstructured":"\u00c1lvarez-Bornstein B, Bordons M. Is funding related to higher research impact? Exploring its relationship and the mediating role of collaboration in several disciplines. J Informetrics. 2021;15(1):101102.","journal-title":"J Informetrics"},{"issue":"3","key":"2226_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1162\/qss_a_00315","volume":"5","author":"W Tian","year":"2024","unstructured":"Tian W, Cai R, Fang Z, Xie Q, Hu Z, Wang X. Research funding in different SCI disciplines: A comparison analysis based on Web of Science. Quant Sci Stud. 2024;5(3):757\u201377.","journal-title":"Quant Sci Stud"},{"key":"2226_CR35","doi-asserted-by":"crossref","unstructured":"Kim B, Yun W, Lee ST, Kim SH, et al. Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia. Scientific reports. 2020;10(1):14297.","DOI":"10.1038\/s41598-020-71386-z"},{"key":"2226_CR36","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2021-151704","volume":"138","author":"SM Tinsley-Vance","year":"2021","unstructured":"Tinsley-Vance SM, Somedeb Ball NAA, Akriti G, Jain, Luis EE, Aguirre D, Kaldas O, Chan E, Padron K, Sweet JE, Lancet, Andrew T, Kuykendall DA, Sallman, Rami S. Komrokji. A Focus on Phenotype and Genotype: Racial \/Ethnic Disparities in Myelodysplastic Syndromes. Blood. 2021;138:1985.","journal-title":"Blood"},{"issue":"3","key":"2226_CR37","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.19689","volume":"205","author":"HL Ribeiro J\u00fanior","year":"2024","unstructured":"Ribeiro J\u00fanior HL. Molecular monitoring of myelodysplastic neoplasm: don\u2019t just watch this space, consider the patient\u2019s ancestry. British journal of haematology. 2024;205(3):759\u201360.","journal-title":"British journal of haematology"},{"key":"2226_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030481","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Eveillard JR, Couturier MA, et al. Asian population is more prone to develop high-risk myelodysplastic syndrome, concordantly with their propensity to exhibit high-risk cytogenetic aberrations. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13030481.","journal-title":"Cancers."},{"issue":"2","key":"2226_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3324\/haematol.2023.284944","volume":"110","author":"MT Villaume","year":"2025","unstructured":"Villaume MT, Savona MR. Pathogenesis and inflammaging in myelodysplastic syndrome. Haematologica. 2025;110(2):283\u201399.","journal-title":"Haematologica"},{"key":"2226_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231183330","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang X, Ma L, Zhang Y, Wei J. Immune dysregulation and potential targeted therapy in myelodysplastic syndrome. Therapeutic advances in hematology. 2023;14:20406207231183330.","journal-title":"Therapeutic advances in hematology"},{"issue":"11","key":"2226_CR41","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1182\/blood.2023023723","volume":"144","author":"M Sirenko","year":"2024","unstructured":"Sirenko M, Bernard E, Creignou M, et al. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood. 2024;144(11):1221\u20139.","journal-title":"Blood"},{"issue":"7","key":"2226_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/17474086.2025.2508505","volume":"18","author":"M Fiumara","year":"2025","unstructured":"Fiumara M, Molteni R, Scorpio G, et al. Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome. Expert Rev Hematol. 2025;18(7):509\u201319.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2226_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1515\/acm-2016-0007","volume":"16","author":"PPL Vasekova","year":"2016","unstructured":"Vasekova PPL. The Differencies in Adult and Pediatric Myelodysplastic Syndrome: A Review. Acta Med Martiniana. 2016;16(2):13\u201322.","journal-title":"Acta Med Martiniana"},{"key":"2226_CR44","doi-asserted-by":"crossref","unstructured":"Cumbo C, Tota G, Anelli L, Zagaria A, Specchia G, Albano F. TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. Int J Mol Sci 2020;21(10).","DOI":"10.3390\/ijms21103432"},{"issue":"2","key":"2226_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020;382(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"2226_CR46","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.2024025464","volume":"145","author":"JS Garcia","year":"2025","unstructured":"Garcia JS, Platzbecker U, Odenike O, et al. Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025;145(11):1126\u201335.","journal-title":"Blood"},{"issue":"11","key":"2226_CR47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41408-022-00744-z","volume":"12","author":"RS Komrokji","year":"2022","unstructured":"Komrokji RS, Singh AM, Ali NA, et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood cancer J. 2022;12(11):148.","journal-title":"Blood cancer J"},{"issue":"1","key":"2226_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40164-025-00652-5","volume":"14","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Lopez-Guerra M, Casta\u00f1o-D\u00edez S, et al. Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study. Experimental Hematol Oncol. 2025;14(1):61.","journal-title":"Experimental Hematol Oncol"},{"key":"2226_CR49","doi-asserted-by":"crossref","unstructured":"Chang YH, Goyama S. Recent advances of cell therapies for AML\/MDS: exploring the therapeutic potential of innate immune cells in AML\/MDS. Int J Hematol 2025.","DOI":"10.1007\/s12185-025-04113-x"},{"issue":"1","key":"2226_CR50","doi-asserted-by":"publisher","first-page":"18677","DOI":"10.1038\/s41598-022-21887-w","volume":"12","author":"N Lee","year":"2022","unstructured":"Lee N, Jeong S, Park MJ, Song W. Deep learning application of the discrimination of bone marrow aspiration cells in patients with myelodysplastic syndromes. Sci Rep. 2022;12(1):18677.","journal-title":"Sci Rep"},{"key":"2226_CR51","doi-asserted-by":"publisher","unstructured":"Elshoeibi AM, Badr A, Elsayed B, Elshoeibi R, Elshoeibi A, et al. Integrating AI and ML in myelodysplastic syndrome diagnosis: state-of-the-art and future prospects. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers16010065.","DOI":"10.3390\/cancers16010065"},{"key":"2226_CR52","doi-asserted-by":"crossref","unstructured":"Wang X, Chen X, Yan M, Kong L. A scientometric analysis of machine learning in schizophrenia neuroimaging: trends and insights (2012\u20132024). Journal of affective disorders. 2012;387:119485, 119485.","DOI":"10.1016\/j.jad.2025.119485"},{"key":"2226_CR53","doi-asserted-by":"publisher","first-page":"104979","DOI":"10.1016\/j.neubiorev.2022.104979","volume":"144","author":"M Sabe","year":"2023","unstructured":"Sabe M, Chen C, Perez N, et al. Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends. Neurosci Biobehav Rev. 2023;144:104979.","journal-title":"Neurosci Biobehav Rev"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02226-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02226-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02226-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:27:30Z","timestamp":1789079250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02226-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02226-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics and Consent to Participate declarations","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"326"}}